Avanos Medical, Inc. is a medical technology company focused on providing medical device solutions to improve the quality of life for patients in North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. The company is headquartered in Alpharetta, Georgia.
| Revenue (TTM) | $715.90M |
| Gross Profit (TTM) | $358.30M |
| EBITDA | $55.90M |
| Operating Margin | 5.38% |
| Return on Equity | -9.18% |
| Return on Assets | 0.95% |
| Revenue/Share (TTM) | $15.43 |
| Book Value | $16.76 |
| Price-to-Book | 1.49 |
| Price-to-Sales (TTM) | 1.63 |
| EV/Revenue | 1.733 |
| EV/EBITDA | 17.17 |
| Quarterly Earnings Growth (YoY) | -21.70% |
| Quarterly Revenue Growth (YoY) | 8.80% |
| Shares Outstanding | $46.85M |
| Float | $46.00M |
| % Insiders | 3.28% |
| % Institutions | 92.03% |
ALPHARETTA, Ga. and NEW YORK, July 2, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) ("Avanos") and American Industrial Partners ("AIP") jointly announced the receipt of all required regulatory approvals to complete the pending acquisition of Avanos by affiliates of investment funds advised by AIP (the "Merger").
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners. Under the terms of the proposed transaction, shareholders of Avanos will receive $25.00 in cash for each share of Avanos that they own. KSF is seeking to determine whether this consideration and the process that led to i.
AVNS' SNS momentum, Nexus Medical integration and AIP deal support growth, but tariff costs, margin pressure and PM&R weakness remain headwinds.
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?
AVNS, BKR and CAG have been added to the Zacks Rank #5 (Strong Sell) List on May 15th, 2026.
Explore Avanos Medical's (AVNS) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Avanos Medical tops Q1 revenue estimates on strong SNS growth, but margin pressure and PM&R weakness weigh on earnings and profitability.
Avanos Medical (AVNS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.26 per share a year ago.
Delivered double-digit organic growth led by Specialty Nutrition Systems segment Generated $0.11 of diluted earnings per share and $0.22 of adjusted diluted earnings per share On April 14, 2026, announced the execution of a definitive agreement to be acquired by certain affiliates of American Industrial Partners ("AIP") in an all-cash offer at an enterprise value of $1.272 billion ALPHARETTA, Ga., May 5, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2026 financial results.
MILWAUKEE, April 23, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Avanos (NYSE: AVNS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with American Industrial.
